Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
6Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Lipella Pharmaceuticals Inc. (LIPO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
3Distinct source URLs
3High confidence
0.753Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
nd Controls (“CMC”) section of the IND application prior to and in conjunction with use in any subsequent clinical trial. Our Analytical Laboratory, Equipment & Supplies Our current preparatory and b…
nd Controls (“CMC”) section of the IND application prior to and in conjunction with use in any subsequent clinical trial. Our Analytical Laboratory, Equipment & Supplies Our current preparatory and b…
Reciprocal relationship from TFX graph: Reciprocal relationship from LIPO graph: nd Controls (“CMC”) section of the IND application prior to and in conjunction with use in any subsequent clinical tri…
Lipella Pharmaceuticals Inc. Customers
Ticker
Name
Confidence
Evidence
BRIDGEWAY-DEVELOPMENT-CORPORATION
BRIDGEWAY-DEVELOPMENT-CORPORATION
85%
), commencing August 1, 2023 and co-terminating with the existing Lease on June 30, 2025. Subsequently effective January 1, 2024, the Company terminated the Fourth Floor Lease early at no penalty upo…
Item 13. Certain Relationships and Related Transactions, and Director Independence 81 Item 14. Principal Accountant Fees and Services 82 PART IV 83 Item 15. Exhibits and Financial Statement Schedules…
Reciprocal relationship from ORANY graph: Reciprocal relationship from LIPO graph: Item 13. Certain Relationships and Related Transactions, and Director Independence 81 Item 14. Principal Accountant …
Item 13. Certain Relationships and Related Transactions, and Director Independence 81 Item 14. Principal Accountant Fees and Services 82 PART IV 83 Item 15. Exhibits and Financial Statement Schedules…
Reciprocal relationship from TFX graph: Reciprocal relationship from LIPO graph: Reciprocal relationship from TFX graph: Reciprocal relationship from LIPO graph: Reciprocal relationship from TFX grap…
OTC-MARKETS-GROUP-INC
OTC-MARKETS-GROUP-INC
62%
), commencing August 1, 2023 and co-terminating with the existing Lease on June 30, 2025. Subsequently effective January 1, 2024, the Company terminated the Fourth Floor Lease early at no penalty upo…
Lipella Pharmaceuticals Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
LIPO-DEBT
Debt stack $264,083
90%
Market cache reports total debt of $264,083.
LIPO-DEBT-10718
Warrants outstanding: 117750
90%
xbrl warrant detail from xbrl 2025-09-30.
Lipella Pharmaceuticals Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Lipella Pharmaceuticals Inc..
Lipella Pharmaceuticals Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Lipella Pharmaceuticals Inc..
Lipella Pharmaceuticals Inc. Extended Supply Chain Network
